Trial
NCT03841773
A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Tonix Pharmaceuticals, Inc.
Collaborators
—
Condition
PTSD
Intervention
TNX-102 SL
Why stopped
Interim Analysis results
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-06